Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Analysis of Anti-inflammatory and Antioxidant Pathways in Lung Diseases by Haem Oxygenase-1 (HO-1) in Induced Sputum and Carbon Monoxide (CO) in Exhaled Air

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by Tel-Aviv Sourasky Medical Center.
Recruitment status was  Active, not recruiting
Information provided by:
Tel-Aviv Sourasky Medical Center Identifier:
First received: February 17, 2010
Last updated: June 8, 2010
Last verified: March 2010
This work will focus on the anti-inflammatory and antioxidant pathways in lung diseases by measuring HO-1 in induced sputum and CO in exhaled air in cases of four respiratory diseases, asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases (OLD) and interstitial lung disease (ILD).

Condition Phase
Lung Diseases
Phase 2

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective

Resource links provided by NLM:

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Primary Outcome Measures:
  • exhaled CO levels [ Time Frame: 2010-2011 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA
induced sputum, exhaled CO levels

Enrollment: 70
Study Start Date: December 2009
Estimated Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Fifty adult male and female patients who had been diagnosed with one or more of the four study diseases and referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center will be enrolled

Inclusion Criteria:

  • Male and female
  • Ages >/= 18 years
  • Diagnosed with one or more lung diseases
  • Referred for sputum induction to the Pulmonary Laboratory in the Tel-Aviv Sourasky Medical Center
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01140685

Sponsors and Collaborators
Tel-Aviv Sourasky Medical Center
Principal Investigator: Elizabeth Fierman, PHD Tel Aviv Sorasky Medical Center
  More Information

Responsible Party: ELIZABETH FIERMAN, PHD, Tel-Aviv Sourasky Medical Center Identifier: NCT01140685     History of Changes
Other Study ID Numbers: TASMC-10-LF-669-CTIL 
Study First Received: February 17, 2010
Last Updated: June 8, 2010
Health Authority: Israel: Ethics Commission

Keywords provided by Tel-Aviv Sourasky Medical Center:
mucus-stimulated (induced sputum)
lung disease (asthma, COPD, ILD and OLD)
HO-1 (heme oxigenase-1)
oxidative stress
CO (carbon monoxide)
The oxidative stress in lung diseases

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Carbon Monoxide
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs processed this record on October 25, 2016